Treatment of Advanced and Metastatic Renal Cancer: A Revolution? Hendrik Van Poppel  European Urology Supplements  Volume 8, Issue 5, Pages 483-488 (April 2009) DOI: 10.1016/j.eursup.2008.12.001 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Progression-free survival rates were significantly higher in patients who received an adjuvant autologous renal tumour cell vaccine (vaccine) than in patients who received no adjuvant vaccine (control) for treatment of advanced renal cell carcinoma after nephrectomy [5]. Reprinted with permission from Elsevier [5]. European Urology Supplements 2009 8, 483-488DOI: (10.1016/j.eursup.2008.12.001) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Based on a combined analysis, overall survival is significantly improved in patients who received cytoreductive nephrectomy plus interferon-α (neph+IFN) versus patients who received interferon-α monotherapy (IFN alone) for metastatic renal cancer [12]. Reprinted with permission from Elsevier [12]. N=nephrectomy; O=observation. European Urology Supplements 2009 8, 483-488DOI: (10.1016/j.eursup.2008.12.001) Copyright © 2008 European Association of Urology Terms and Conditions